Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reiterated by investment analysts at Oppenheimer in a note issued to investors on Wednesday.

Other analysts have also issued reports about the stock. BidaskClub lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Needham & Company LLC boosted their target price on shares of Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Jefferies Group boosted their target price on shares of Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Deutsche Bank boosted their target price on shares of Neurocrine Biosciences to $97.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Finally, Leerink Swann boosted their target price on shares of Neurocrine Biosciences from $90.00 to $96.00 and gave the company an “outperform” rating in a research note on Tuesday, February 20th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $95.23.

How to Become a New Pot Stock Millionaire

Shares of NBIX stock opened at $84.83 on Wednesday. The stock has a market cap of $7,578.43, a price-to-earnings ratio of -51.73 and a beta of 0.31. Neurocrine Biosciences has a one year low of $39.21 and a one year high of $92.98. The company has a debt-to-equity ratio of 0.99, a quick ratio of 10.20 and a current ratio of 10.20.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same period in the prior year, the company earned ($0.51) earnings per share. sell-side analysts predict that Neurocrine Biosciences will post -0.23 EPS for the current fiscal year.

In related news, insider Haig P. Bozigian sold 1,625 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 105,983 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the sale, the chief executive officer now owns 339,482 shares of the company’s stock, valued at $27,243,430.50. The disclosure for this sale can be found here. Insiders sold 399,589 shares of company stock valued at $32,443,795 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in NBIX. Perceptive Advisors LLC raised its holdings in Neurocrine Biosciences by 33.9% in the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after purchasing an additional 1,214,000 shares in the last quarter. American Century Companies Inc. raised its holdings in Neurocrine Biosciences by 1,257.3% in the fourth quarter. American Century Companies Inc. now owns 490,648 shares of the company’s stock worth $38,069,000 after purchasing an additional 454,500 shares in the last quarter. Millennium Management LLC raised its holdings in Neurocrine Biosciences by 357.3% in the fourth quarter. Millennium Management LLC now owns 534,566 shares of the company’s stock worth $41,477,000 after purchasing an additional 417,661 shares in the last quarter. Renaissance Technologies LLC bought a new position in Neurocrine Biosciences in the fourth quarter worth about $30,046,000. Finally, Allianz Asset Management GmbH raised its holdings in Neurocrine Biosciences by 773.4% in the fourth quarter. Allianz Asset Management GmbH now owns 350,325 shares of the company’s stock worth $27,182,000 after purchasing an additional 310,214 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences’ (NBIX) Buy Rating Reiterated at Oppenheimer” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/neurocrine-biosciences-nbix-buy-rating-reiterated-at-oppenheimer/1955752.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.